IL191061A0 - Triazole compounds as lipoxygenase inhibitors - Google Patents

Triazole compounds as lipoxygenase inhibitors

Info

Publication number
IL191061A0
IL191061A0 IL191061A IL19106108A IL191061A0 IL 191061 A0 IL191061 A0 IL 191061A0 IL 191061 A IL191061 A IL 191061A IL 19106108 A IL19106108 A IL 19106108A IL 191061 A0 IL191061 A0 IL 191061A0
Authority
IL
Israel
Prior art keywords
triazole compounds
lipoxygenase inhibitors
lipoxygenase
inhibitors
triazole
Prior art date
Application number
IL191061A
Other languages
English (en)
Original Assignee
Biolipox Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolipox Ab filed Critical Biolipox Ab
Publication of IL191061A0 publication Critical patent/IL191061A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL191061A 2005-10-31 2008-04-27 Triazole compounds as lipoxygenase inhibitors IL191061A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73148105P 2005-10-31 2005-10-31
PCT/GB2006/004010 WO2007051982A1 (en) 2005-10-31 2006-10-27 Triazole compounds as lipoxygenase inhibitors

Publications (1)

Publication Number Publication Date
IL191061A0 true IL191061A0 (en) 2008-12-29

Family

ID=35810092

Family Applications (1)

Application Number Title Priority Date Filing Date
IL191061A IL191061A0 (en) 2005-10-31 2008-04-27 Triazole compounds as lipoxygenase inhibitors

Country Status (14)

Country Link
US (1) US20090186918A1 (enExample)
EP (1) EP1943234A1 (enExample)
JP (1) JP2009513691A (enExample)
KR (1) KR20080067364A (enExample)
CN (1) CN101300236A (enExample)
AU (1) AU2006310367A1 (enExample)
BR (1) BRPI0618079A2 (enExample)
CA (1) CA2627516A1 (enExample)
EA (1) EA200801108A1 (enExample)
IL (1) IL191061A0 (enExample)
NO (1) NO20081888L (enExample)
NZ (1) NZ567605A (enExample)
WO (1) WO2007051982A1 (enExample)
ZA (1) ZA200803636B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
JP2009513692A (ja) * 2005-11-01 2009-04-02 バイオリポックス エービー 炎症の治療に有用なピラゾール化合物
AU2008247102B2 (en) 2007-05-03 2011-11-24 Pfizer Limited 2 -pyridine carboxamide derivatives as sodium channel modulators
WO2011028651A1 (en) * 2009-09-01 2011-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of human 15-lipoxygenase-1
KR101810975B1 (ko) 2010-07-08 2017-12-20 에스케이바이오팜 주식회사 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물
EP2616458B1 (en) * 2010-09-13 2016-07-20 Basf Se Pyridine compounds for controlling invertebrate pests ii
EP2635565A1 (en) 2010-11-04 2013-09-11 Amgen Inc. 5 -cyano-4, 6 -diaminopyrimidine or 6 -aminopurine derivatives as pi3k- delta inhibitors
HK1215256A1 (zh) 2012-11-20 2016-08-19 Vertex Pharmaceuticals Incorporated 用作吲哚胺2，3-二氧化酶的抑制劑的化合物
KR101612179B1 (ko) * 2013-04-19 2016-04-12 영남대학교 산학협력단 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물
US9403833B2 (en) * 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
EP3108883A1 (en) * 2015-06-22 2016-12-28 Fundació Institut de Recerca Biomèdica de Bellvitge Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway
CN111057058B (zh) * 2020-01-03 2021-02-02 浙江工业大学 一种制备1H-[1,2,3]-三唑并[4,5-c]喹啉类化合物的方法
CN113466395B (zh) * 2021-08-03 2023-11-21 杭州微源检测技术有限公司 一种检测瑞戈非尼和中间体药物中4-氯-3-三氟甲基异氰酸苯酯含量的方法
CN116082253B (zh) * 2023-02-25 2025-04-25 浙大城市学院 一种1-n-取代的1,2,3-三唑-4-甲酰胺衍生物及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1306260C (en) * 1985-10-18 1992-08-11 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives
FR2639636B1 (fr) * 1988-11-30 1994-03-04 Novapharme Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant
US5258397A (en) * 1988-11-30 1993-11-02 Novapharme 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions
US5464860A (en) * 1988-11-30 1995-11-07 Novapharme N(pyrazol-3-yl) benzamides and pharmaceutical compositions
ATE198601T1 (de) * 1992-05-20 2001-01-15 Merck & Co Inc Ester derivate von 4-aza-steroiden
JPH07508038A (ja) * 1992-05-20 1995-09-07 メルク　エンド　カンパニー　インコーポレーテッド ４−アザステロイドの１７−エーテル及びチオエーテル
US6372770B1 (en) * 1994-10-12 2002-04-16 Euro-Celtique, S.A. Benzoxazoles
US5663357A (en) * 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6291476B1 (en) * 1999-05-12 2001-09-18 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
EP1254115A2 (en) * 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
GB0011094D0 (en) * 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
KR20030030029A (ko) * 2000-09-22 2003-04-16 니혼노야쿠가부시키가이샤 Ｎ-(4-피라졸릴)아미드 유도체 및 농원예용 약제 그리고그 사용방법
JP4465133B2 (ja) * 2001-02-08 2010-05-19 クミアイ化学工業株式会社 イソオキサゾリン誘導体及びこれを有効成分とする除草剤
DE10110750A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE60235114D1 (de) * 2001-11-01 2010-03-04 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
TWI263497B (en) * 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
EP1562911B1 (en) * 2002-11-01 2010-01-06 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
US7382703B2 (en) * 2002-12-13 2008-06-03 Matsushita Electric Industrial Co., Ltd. Optical disc apparatus
US7429581B2 (en) * 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
WO2004080999A1 (en) * 2003-03-14 2004-09-23 Biolipox Ab Pyrazole compounds useful in the treatment of inflammation
SE0300705D0 (sv) * 2003-03-14 2003-03-14 Biolipox Ab New compounds
US7429603B2 (en) * 2003-04-25 2008-09-30 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
WO2006032852A1 (en) * 2004-09-20 2006-03-30 Biolipox Ab Pyrazole compounds useful uin the treatment of inflammation
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
JP2009513692A (ja) * 2005-11-01 2009-04-02 バイオリポックス エービー 炎症の治療に有用なピラゾール化合物

Also Published As

Publication number Publication date
BRPI0618079A2 (pt) 2011-08-16
WO2007051982A1 (en) 2007-05-10
EP1943234A1 (en) 2008-07-16
EA200801108A1 (ru) 2008-10-30
KR20080067364A (ko) 2008-07-18
JP2009513691A (ja) 2009-04-02
CN101300236A (zh) 2008-11-05
AU2006310367A1 (en) 2007-05-10
US20090186918A1 (en) 2009-07-23
CA2627516A1 (en) 2007-05-10
ZA200803636B (en) 2009-10-28
NZ567605A (en) 2010-07-30
NO20081888L (no) 2008-07-01

Similar Documents

Publication Publication Date Title
IL191061A0 (en) Triazole compounds as lipoxygenase inhibitors
ZA200709994B (en) Neurotherapeutic Azole Compounds
IL185185A0 (en) Azolylacylguanidines as ??-secretase inhibitors
IL190450A0 (en) Substituted pyrazole compounds
ZA200705718B (en) Substituted triazole derivatives as oxytocin antagnists
EP1847531A4 (en) PYRAZOLE DERIVATIVE
ZA200805000B (en) Compositions of lipoxygenase inhibitors
GB0503962D0 (en) Compounds
ZA200806358B (en) Triazole Derivatives
GB0502418D0 (en) Compounds
EP1856040A4 (en) NEW LIPOXYGENASE INHIBITORS
GB0502316D0 (en) Compounds
IL187059A0 (en) Mono-lysine salts of azole compounds
GB0502310D0 (en) Compounds
GB0503961D0 (en) Compounds
GB0505084D0 (en) Compounds
AP2007004220A0 (en) Motilide compounds
ZA200802786B (en) Substituted pyrazole compounds
EP1907385A4 (en) LINKS
GB0501985D0 (en) Compounds
GB0503145D0 (en) Compounds
HK1117843A (en) Triazole compounds as lipoxygenase inhibitors
GB0501984D0 (en) Compounds
EP1867650A4 (en) HYDROXYMETHYLBORVERBINDUNGEN
GB0512626D0 (en) Inhibitor compounds